Alzheimer's disease pipeline

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

Apr 18, 2025

Groundbreaking Alzheimer’s Therapies: From Pipeline to Patient Care

Feb 26, 2025

Alzheimer’s Treatment: Latest Breakthroughs and Advancements in Therapeutic Development

Feb 12, 2025

Semaglutide: A Potential Game-Changer in Reducing Alzheimer’s Disease Risk

Feb 12, 2025

Can Remternetug Solve the Puzzle of Alzheimer’s?

Feb 12, 2025

What is the Link Between Alzheimer’s and Menopause?

Feb 12, 2025

Exploring the Current Alzheimer’s Disease Drug Development Pipeline

Feb 12, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Jul 08, 2024

A New Dawn in Alzheimer’s Disease Treatment: Eli Lilly’s Donanemab Wins FDA Approval

Newsletter/Whitepaper